New Clinical Trials for January 2016 | Cancer Currents | Norris Cotton Cancer Center
Skip to main content
x
Norris Cotton Cancer Center
In This Section

New Clinical Trials for January 2016

Konstantin Dragnev, Professor, Cancer Mechanism

  • CALGB
    Randomized Phase II study of maintenance pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first-line chemotherapy
  • ECOG-ACRIN
    Molecular Analysis for Therapy Choice (MATCH)
  • Hanmi Pharmaceutical Co.
    A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive Non-Small Cell Lung Cancer (NSCLC) after treatment with an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI)

Shudong Jiang, Assistant Professor, Cancer Imaging and Radiobiology

  • NIH
    Development of a mobile NIRST breast imaging unit

Peter Kaufman, Associate Professor, Molecular Therapeutics

  • Merck & Company
    A Phase II clinical trial of pembrolizumab (MK-3475) as monotherapy for metastatic Triple-Negative Breast Cancer (mTNBC) (KEYNOTE-086)
  • ECOG-ACRIN
    A randomized Phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
  • Eisai
    An open-label, single-arm multicenter Phase 1b/2 study to evaluate the efficacy and safety of eribulin mesylate in combination with pembrolizumab in subjects with metastatic Triple-Negative Breast Cancer (mTNBC)

Frederick Lansigan, Assistant Professor, Molecular Therapeutics

  • Pharmaceuticals
    A multicenter, open-label study of the Histone Deacetylase inhibitor (HDACi), abexinostat, in combination with ibrutinib, in subjects with relapsed or refractory lymphomas
  • Gilead Sciences
    A Phase 2, open-label study evaluating the efficacy, safety, tolerability, and pharmacodynamics of GS-9973 in subjects with relapsed or refractory hematologic malignancies

Lionel Lewis, Professor, Molecular Therapeutics

  • AbbVie
    A Phase 1b/2 study of duvelisib and venetoclax in subjects with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, or indolent or aggressive non-Hodgkin lymphoma, who have not previously received a Bcl-2 or Pl3K inhibitor
  • Novartis Pharmaceuticals
    A Phase I, multicenter, open-label, single-sequence drug-drug interaction study to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors
  • GSK
    An open-label Phase 1 study to evaluate the effects of Dabrafenib (GSK2118436) on the single dose pharmacokinetics of an OATP1B1/1B3 substrate and of a CYP3A4 substrate in subjects with BRAF V600 mutation positive tumors

Kenneth Meehan, Professor, Immunology and Cancer Immunotherapy

  • DHMC
    Patient and caregiver costs following hematopoietic stem cell transplantation

Tracy Onega, Associate Professor, Cancer Control

  • DHMC
    NCCC registry shared resource

William Rigby, Professor, Immunology and Cancer Immunotherapy

  • AbbVie
    A Phase 3, multicenter, blinded, Long-Term Extension (LTE) study in rheumatoid arthritis subjects who have completed a preceding Phase 3 Randomized Controlled Trial (RCT) with ABT-494
  • AbbVie
    A Phase 3, randomized, double-blind study comparing ABT-494 monotherapy to Methotrexate (MTX) in subjects with moderately to severely active rheumatoid arthritis with inadequate response to MTX

Richard Rothstein, Joseph M. Huber Professor, Cancer Epidemiology

  • BAROnova, Inc.
    Endoscopic treatment for weight reduction in patients with obesity using the transPyloric shuttle system: A multicenter, prospective, randomized, double-blind, sham controlled, parallel-design study

0